JSPRW — Jasper Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1788028 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -10,952,000 | -1,174,000 | 21,184,000 | 14,144,000 | 17,784,000 |
| Dec 2025 | 0 | — | -15,839,000 | -9,101,000 | 35,779,000 | 28,692,000 | 31,628,000 |
| Sep 2025 | 0 | — | -19,166,000 | -18,736,000 | 57,469,000 | 50,899,000 | 45,898,000 |
| Jun 2025 | 0 | — | -27,076,000 | -26,723,000 | 46,466,000 | 39,510,000 | 22,965,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-68,867,000
Investing CF
$1,000
Financing CF
$34,211,000
CapEx
$-370,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-317,844,000
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-73,033,000
Pretax Income TTM
$-55,734,000
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -83,883,000 | -75,801,000 | 35,779,000 | 31,628,000 | — | -77,161,000 |
| Dec 2024 | 0 | -76,239,000 | -71,269,000 | 79,899,000 | 18,225,000 | — | -62,602,000 |
| Dec 2023 | 0 | -68,861,000 | -64,465,000 | 94,892,000 | 16,452,000 | — | -52,067,000 |
| Dec 2022 | 0 | -51,196,000 | -37,685,000 | 48,361,000 | 12,372,000 | — | -45,858,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMGN | AMGEN INC | $207.87B | $385.16 | — |
| GILD | GILEAD SCIENCES, INC. | $161.66B | $130.21 | — |
| ARGX | ARGENX SE | $53.42B | $853.82 | — |
| RVMD | Revolution Medicines, Inc. | $39.87B | $187.53 | — |
| BIIB | BIOGEN INC. | $29.99B | $202.95 | — |
News headlines (Yahoo Finance, 1h cache)
Jasper gets a lifeline in merger with immune drugmaker Kira
2026-07-17 11:54 · Yahoo
Jasper Therapeutics Announces Merger with Kira Pharmaceuticals
2026-07-16 21:15 · Yahoo
Chronic Spontaneous Urticaria Market Heats Up as Pharma Companies Race to Address Unmet Needs | DelveInsight
2026-06-24 14:31 · Yahoo
Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now
2026-06-03 13:55 · Yahoo
Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
2026-06-01 12:00 · Yahoo
Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-14 20:05 · Yahoo
Evercore ISI Lowers its Price Target on Jasper Therapeutics (JSPR) to $7
2026-04-07 14:29 · Yahoo
Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
2026-03-30 20:30 · Yahoo
Why UBS Started Jasper Therapeutics (JSPR) at Neutral Despite Progress in Briquilimab
2026-03-29 20:50 · Yahoo
Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference
2026-02-24 21:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.